CytomX Therapeutics Inc
1 day chart
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines and checkpoint inhibitors (CPIs). Its clinical pipeline also includes cancer immunotherapeutic candidates. Its product candidates include CX-2029, CX-904, CX-2051, CX-801 and BMS-986288. Its CX-2029 is a Probody ADC targeting CD71 for the treatment of patients with squamous non-small cell lung carcinoma (sqNSCLC) and esophageal cancers.
Buy US stocks in Australia starting with CTMX. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CTMX
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.